PARKINSON DISEASE (Disorder)NCT07534397

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

A study testing transcranial direct current stimulation in people with PARKINSON DISEASE (Disorder), run by The University of Texas at Dallas at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts

Official record

Search all trials

Trial summary

The purpose of this research study is to examine the effects of transcranial Direct Current Stimulation (tDCS) on verbal retrieval and cognition and sensorimotor control and to determine if tDCS can be used as a way to improve retrieval, sensory, and motor abilities in individuals with Parkinson's disease (PD). Read more about this study

Who is it for?: Ages 50 to 90 years
Conditions the study is for: PARKINSON DISEASE (Disorder)
What is being tested?: transcranial direct current stimulation
Type of treatment: Medical device
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 20 participants
Where: 1 siteUnited States
Study dates: 15 Sep 2026to 31 Oct 2027
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 50 to 90 years
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score < 40 or a T-score <-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT)
50 - 90 years old
Capable of understanding and signing an informed consent (able to answer consent comprehension questions)
Fluent in speaking and reading English

Who cannot join

A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues:
Montreal Cognitve Assessment (MOCA) score <23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling);
history of seizures;
unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy);
suffering from severe or frequent headaches;
unstable or uncontrolled neuropsychiatric illness;

Show all 36Show fewer

severe traumatic brain injury (based on the Ohio State TBI Identification; Method);
brain tumor; stroke; present drug abuse/misuse;
brain tumor;
serious or life-threatening diseases, including congestive heart failure, chronic obstructive pulmonary disease, or active malignancy;
Huntington's disease;
stroke;
cranial implants or skull defects that affect tDCS administration;
implanted brain medical devices, including, deep brain stimulators (DBS);
implanted pacemakers;
any electrically, magnetically, or mechanically activated implants;
cardiac, neural, or medication implants;
vascular clips or other electrically sensitive support systems in the brain;
damaged skin at the sites of stimulation (the device should only be used on healthy, intact skin, as wounds may alter resistance to current);
skin conditions such as dermatitis, psoriasis, or eczema;
pregnant women;
diagnosis of just dysarthria;
Use of medications that interact with or potentially interact with tDCS or EEG effects:
anti-convulsants;
carbamazepine;
sulpiride;
pergolide;
lorazepam;
rivastigmine;
dextromethorphan;
D-cycloserine;
flunarizine;
ropinirole;
citalopram;
stimulants;
Additionally, non-English speakers will be excluded because not all of the screening forms, questionnaires, and tests are available in languages other than English.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site

Callier Clinical Center, The University of Texas at Dallas
Richardson, Texas, 75080

Other trials in United States

About this study

Read the detailed description

Objective: Based on models of semantic memory retrieval developed, under which the pre-supplementary motor area (preSMA) of the dorsomedial frontal lobes play an important role, the study will examine the treatment of cognitive deficits in PD with HD tDCS applied to the preSMA to improve function in neural circuits supporting verbal retrieval. In addition, as the preSMA is implicated in motor planning and sequencing, the study also will explore whether HD tDCS applied to the preSMA will have an effect on speech and gait.

Specific Aims:

Examine the therapeutic effects on verbal retrieval function by modulating the preSMA using HD tDCS.
Examine the therapeutic effects on speech production and processing by modulating the preSMA using HD tDCS
Examine the therapeutic effects on gait and balance by modulating the preSMA using HD tDCS

Hypotheses:

: Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve verbal fluency (i.e, phonemic and category fluency on Controlled Word Association Test) as primary outcome measures.
: Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve speech sequencing.
: Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve general motor sequencing

Conditions: PARKINSON DISEASE (Disorder)
Being tested: transcranial direct current stimulation, Sham transcranial direct current stimulation
Keywords: transcranial direct current stimulation (tDCS), Parkinson's Disease, electroencephalography (EEG), presupplementary motor area (preSMA), verbal memory, speech sequencing, motor sequencing
Medical subject headings: Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

transcranial direct current stimulationDevice
Also called transcranial electric stimulation, tDCS, tES
Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.
Sham transcranial direct current stimulationDevice
Also called sham tDCS, Sham trascranial electric stimulation, sham tES
Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.

Study groups in NCT07534397
Study group	Role	What they receive
Transcranial direct current stimulation	Experimental	Transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds. Other Names: tDCS 1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10 Receives: Device: transcranial direct current stimulation
Sham transcranial direct current stimulation	Sham comparator	Sham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes. Receives: Device: Sham transcranial direct current stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency
valuation of treatment group differences in change on Category Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency
Evaluation of treatment group differences in change on Category Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Measured: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on Phonemic Fluency
Evaluation of treatment group differences in change on Phonemic Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Phonemic Fluency
Evaluation of treatment group differences in change on Phonemic Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Measured: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment

Secondary outcomes (16)

Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during overt reading
Evaluation of treatment group differences in change in speaking rate from baseline to 1-week post-treatment. Metric: syllables per second on a passage reading task (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during overt reading
Evaluation of treatment group differences in change on speaking rate from baseline to 2-months post-treatment. Metric: Syllables per second during a reading passage (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during self-generated speech
Evaluation of treatment group differences in change in speaking rate from baseline to 1-week post-treatment. Metric: Syllables per second during self-generated speech (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during self-generated speech
Evaluation of treatment group differences in change on speaking rate from baseline to 2-months post-treatment. Metric: Syllables per second during self-generated speech (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score.
Evaluation of treatment group differences in change in Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score from baseline to 1-week post-treatment. Metric: Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score (minimum=0; maximum=132)
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-month Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score.
Evaluation of treatment group differences in change in Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score from baseline to 2-month post-treatment. Metric: Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score (minimum=0; maximum=132)
Measured: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during overt reading
Evaluation of treatment group differences in change in speaking rhythm from baseline to 1-week post-treatment. Metric: coefficient of variation of syllable duration on a passage reading task (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during overt reading
Evaluation of treatment group differences in change on speaking rhythm from baseline to 2-months post-treatment. Metric: Coefficient of variation of syllable duration during a reading passage (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during self-generated speech
Evaluation of treatment group differences in change in speaking rhythm from baseline to 1-week post-treatment. Metric: Coefficient of variation of syllable duration during self-generated speech (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during self-generated speech
Evaluation of treatment group differences in change on speaking rhythm from baseline to 2-months post-treatment. Metric: Coefficient of variation of syllable duration during self-generated speech (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during overt reading
Evaluation of treatment group differences in change in speaking pause time from baseline to 1-week post-treatment. Metric: Pause time as percentage of total speaking time on a passage reading task (minimum=0%; maximum=100%).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during overt reading
Evaluation of treatment group differences in change on speaking pause time from baseline to 2-months post-treatment. Metric: Pause time as percentage of total speaking time during a reading passage (minimum=0%; maximum=100%).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during self-generated speech
Evaluation of treatment group differences in change in speaking pause time from baseline to 1-week post-treatment. Metric: Pause time as percentage of total speaking time during self-generated speech (minimum=0%; maximum=100%).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during self-generated speech
Evaluation of treatment group differences in change on speaking pause time from baseline to 2-months post-treatment. Metric: Pause time as percentage of total speaking time during self-generated speech (minimum=0%; maximum=100%).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Freezing of Gate during the timed up and go task
Evaluation of treatment group differences in change in freezing of gate from baseline to 1-week post-treatment. Metric: Timed up and go time (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-month Post-treatment on Freezing of Gate during the timed up and go task
Evaluation of treatment group differences in change in freezing of gate from baseline to 2-month post-treatment. Metric: Timed up and go time (minimum=0; no maximum).
Measured: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 Sep 202631 Oct 2027

First posted16 Apr 2026
Study start15 Sep 2026
Primary completion31 Oct 2027 (estimated)
Study completion31 Oct 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Model description: Participants with PD will be randomly assigned to receive 10-sessions of either active tDCS at 1 mA targeting pre-SMA or sham. Stimulation (1 mA anodal) will target the presupplementary motor area (preSMA) for 20 minutes over 10 sessions. Hypothesis (1): Active HD tDCS will improve language function for verbal output and word finding (primary outcomes) will be Controlled Oral Word Association Test (COWAT) letter fluency, category fluency, and visual confrontation naming speed. Hypotheses (2): Active HD tDCS will improve from baseline speech rate / rhythm (i.e., mean speaking rate and coefficient of variation of syllable duration during speaking tasks) as secondary outcome measures post intervention. Hypotheses (3): Active HD tDCS will improve from baseline gait/freezing of gait metrics as secondary outcome measures post intervention.
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 20 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07534397
Sponsor's protocol ID: IRB-26-35
Status last verified: Nov 2026
First submitted: 9 Apr 2026
Last updated: 3 Nov 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: Yes
Individual data sharing: Yes: De-identified individual participant data (IPD) that underlie the results reported in published articles, including baseline demographic and clinical characteristics required to replicate the findings, will be made available.

Interested in taking part?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease

All PARKINSON DISEASE (Disorder) trials

Study at a glance

From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation
ClinicalTrials.gov ID: NCT07534397
Acronym / sponsor ID: IRB-26-35
Conditions: PARKINSON DISEASE (Disorder)
Keywords: transcranial direct current stimulation (tDCS), Parkinson's Disease, electroencephalography (EEG), presupplementary motor area (preSMA), verbal memory, speech sequencing, motor sequencing
Study type: Interventional
Recruitment status: Enrolling by invitation
Enrolment: 20 participants (estimated)
Lead sponsor: The University of Texas at DallasUniversity, hospital or other
Collaborators: University of Texas Southwestern Medical Center
Study start: 15 Sep 2026 (actual)
Primary completion: 31 Oct 2027 (estimated)
Study completion: 31 Oct 2027 (estimated)
First posted: 16 Apr 2026 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Specific Aims:

Examine the therapeutic effects on verbal retrieval function by modulating the preSMA using HD tDCS.
Examine the therapeutic effects on speech production and processing by modulating the preSMA using HD tDCS
Examine the therapeutic effects on gait and balance by modulating the preSMA using HD tDCS

Hypotheses:

: Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve verbal fluency (i.e, phonemic and category fluency on Controlled Word Association Test) as primary outcome measures.
: Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve speech sequencing.
: Active HD tDCS (1 ma anodal HD tDCS to the preSMA compared to sham) will improve general motor sequencing

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 2
Model description: Participants with PD will be randomly assigned to receive 10-sessions of either active tDCS at 1 mA targeting pre-SMA or sham. Stimulation (1 mA anodal) will target the presupplementary motor area (preSMA) for 20 minutes over 10 sessions. Hypothesis (1): Active HD tDCS will improve language function for verbal output and word finding (primary outcomes) will be Controlled Oral Word Association Test (COWAT) letter fluency, category fluency, and visual confrontation naming speed. Hypotheses (2): Active HD tDCS will improve from baseline speech rate / rhythm (i.e., mean speaking rate and coefficient of variation of syllable duration during speaking tasks) as secondary outcome measures post intervention. Hypotheses (3): Active HD tDCS will improve from baseline gait/freezing of gait metrics as secondary outcome measures post intervention.

Arm	Type	Receives
Transcranial direct current stimulation	Experimental	Device: transcranial direct current stimulationTranscranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds. Other Names: tDCS 1 milliamp tDCS High definition tDCS High definition transcranial direct current stimulator, Neuroelectrics Starstim tES, SN E20200930-10
Sham transcranial direct current stimulation	Sham comparator	Device: Sham transcranial direct current stimulationSham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.

Who may qualify

Ages: 50 to 90 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (4 listed)

Diagnosed with PD having a verbal fluency deficit based on neuropsychological test (T-score < 40 or a T-score <-1.0 SD below the average T-score): Semantic Object Retrieval Test (SORT), COWAT (both letter and category fluency), Boston Naming Test (BNT), Rey Auditory Verbal Learning Test (RAVLT)
50 - 90 years old
Capable of understanding and signing an informed consent (able to answer consent comprehension questions)
Fluent in speaking and reading English

Key exclusion criteria (36 listed)

A potentially study-confounding, tDCS-contraindicated, or EEG-contraindicated psychological, neuropsychiatric, neurological, or other medical issues:
Montreal Cognitve Assessment (MOCA) score <23, unless an accompanying study partner/caregiver is with them and we can obtain the written consent of both the participant and the participant's accompanying study partner/caregiver (i.e., the participant's spouse, adult child, parent, or adult sibling);
history of seizures;
unexplained episodes of loss of consciousness (as these may be related to brain alterations or epilepsy);
suffering from severe or frequent headaches;

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
transcranial direct current stimulationAlso: transcranial electric stimulation, tDCS, tESTranscranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. Stimulation will consist of 1 milliamp stimulation, with anodal stimulation delivered at electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, then remain at 1 milliamp of stimulation over 20 minutes, and finally ramping down at to 0 milliamps over 60 seconds.	Device	Transcranial direct current stimulation
Sham transcranial direct current stimulationAlso: sham tDCS, Sham trascranial electric stimulation, sham tESSham transcranial direct current stimulation will be delivered via a Neuroelectrics Starstim tES. The sham setup will consist of anodal electrode Fz (International 10/10 System for electroencephalography electrode placement) and electrodes F7, FP1, FP2, and F8 as returns. All electrodes are 1 cm diameter Ag/AgCl electrodes and make contact with the scalp via connective gel. Stimulation will linearly ramp up from 0 milliamps to 1 milliamp over 60 seconds, ramp down to 0 milliamps over 60 seconds and then be left off for 20 minutes.	Device	Sham transcranial direct current stimulation

Primary outcome

Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
valuation of treatment group differences in change on Category Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Evaluation of treatment group differences in change on Category Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Treatment group differences in change from Baseline to 1-week Post-Treatment on Phonemic Fluency
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Evaluation of treatment group differences in change on Phonemic Fluency from baseline to 1-week post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)
Treatment group differences in change from Baseline to 2-months Post-Treatment on Phonemic Fluency
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment
Evaluation of treatment group differences in change on Phonemic Fluency from baseline to 2-months post-treatment. Metric: Number of Correct Items Generated (minimum=0 words; no maximum)

16 secondary outcomes

Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during overt reading
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during overt reading
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rate during self-generated speech
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rate during self-generated speech
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score.
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-month Post-treatment on Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale Part III score.
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during overt reading
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during overt reading
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Rhythm during self-generated speech
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Rhythm during self-generated speech
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during overt reading
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during overt reading
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Speaking Pause Time during self-generated speech
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Speaking Pause Time during self-generated speech
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: change from baseline to 2-months Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-treatment on Freezing of Gate during the timed up and go task
Time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-month Post-treatment on Freezing of Gate during the timed up and go task
Time frame: Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) that underlie the results reported in published articles, including baseline demographic and clinical characteristics required to replicate the findings, will be made available.

Related trials for PARKINSON DISEASE (Disorder)

Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

John Hart, MD principal investigator

Callier Clinical Research Center, The University of Texas at Dallas

Saul A Frankford, PhD principal investigator

Callier Clinical Research Center, The University of Texas at Dallas

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing transcranial direct current stimulation in people with PARKINSON DISEASE (Disorder), run by The University of Texas at Dallas at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 36 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency (time frame: Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07534397.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.